|
ZNF180 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.46149800331841E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.47024622979097E-13 |
| Normal-vs-Stage2 |
9.45430000953706E-09 |
| Normal-vs-Stage3 |
1.62969637784727E-12 |
| Normal-vs-Stage4 |
1.11022302462516E-16 |
| Stage1-vs-Stage2 |
9.780200E-02 |
| Stage1-vs-Stage3 |
8.278000E-02 |
| Stage1-vs-Stage4 |
6.358700E-03 |
| Stage2-vs-Stage3 |
6.997000E-03 |
| Stage2-vs-Stage4 |
4.761100E-04 |
| Stage3-vs-Stage4 |
1.735450E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.56541446472147E-14 |
| Normal-vs-AfricanAmerican |
2.56950000165901E-08 |
| Normal-vs-Asian |
3.51929596575928E-11 |
| Caucasian-vs-AfricanAmerican |
8.510600E-01 |
| Caucasian-vs-Asian |
2.050200E-01 |
| AfricanAmerican-vs-Asian |
4.985000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.93500770961919E-12 |
| Normal-vs-Female |
1.66966440673377E-12 |
| Male-vs-Female |
5.404000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66766600528945E-12 |
| Normal-vs-Age(41-60Yrs) |
1.86650694899981E-12 |
| Normal-vs-Age(61-80Yrs) |
1.66822111680176E-12 |
| Normal-vs-Age(81-100Yrs) |
6.034300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.944600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.661800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.950600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.269400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.755600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.383200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.83847999999376E-05 |
| Classical-VS-Follicular |
3.103600E-02 |
| Classical-VS-Other |
5.673800E-01 |
| Classical-VS-Normal |
2.25874874359988E-12 |
| Tall-VS-Follicular |
4.30950000018804E-07 |
| Tall-VS-Other |
3.695200E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.638600E-01 |
| Follicular-VS-Normal |
9.32150023835732E-10 |
| Other-VS-Normal |
3.578900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.43205455774387E-12 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
2.664800E-03 |
|
|
